Dineo Khabele, MD, FACOG, FACS

Director of Gynecological Oncology Translational Research
Associate Professor in Obstetrics and Gynecology
Associate Professor in Cancer Biology
Member of the Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center

Dr. Dineo Khabele is a physician and surgeon who diagnoses and treats women with gynecologic malignancies. As a physician scientist, she conducts clinical and translational research studies and has received federal grants and foundation awards. She has presented her work nationally and internationally and has authored over 40 manuscripts. As an educator, Dr. Khabele is committed to raising awareness about women’s cancers and cancer health disparities and she is actively involved in mentoring and training the next generation of physicians and scientists. Prior to joining Vanderbilt in 2008, she was the Director of Gynecologic Oncology at Meharry Medical College where she is adjunct faculty. She is a member of several medical societies and sits on the medical and scientific advisory boards including the Ovarian Cancer National Alliance. She is also involved in policy making for the Tennessee Breast and Cervical Cancer Screening Program and served on the Governor-Appointed Task Force to Eliminate Cervical Cancer in Tennessee. She uses her personal hobby of running to advocate for healthy lifestyles and raise awareness about cancer.

She is board certified in Obstetrics and Gynecology and Gynecologic Oncology and obtained undergraduate and medical degrees from Columbia College and Columbia College of Physicians and Surgeons of Columbia University in New York. She completed her residency in obstetrics and gynecology at The New York Presbyterian Hospital, Weill-Cornell University Medical Center, followed by a clinical fellowship in gynecologic oncology and post-doctoral research training in cancer biology at Albert Einstein College of Medicine and Montefiore Medical Center.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Incidental placenta increta at the time of prophylactic hysterectomy for Lynch syndrome: Insights into individualized decision-making and surgical timing. Nielsen TA, David SN, Desouki MM, Crispens MA, Khabele D (2015) Gynecol Oncol Rep : 20-2
    › Primary publication · 26793766 (PubMed) · PMC4688886 (PubMed Central)
  2. Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer. Wilson AJ, Saskowski J, Barham W, Khabele D, Yull F (2015) Mol Cancer : 192
    › Primary publication · 26552746 (PubMed) · PMC4640396 (PubMed Central)
  3. Results of a Health Education Message Intervention on HPV Knowledge and Receipt of Follow-up Care among Latinas Infected with High-risk Human Papillomavirus. Sanderson M, Khabele D, Brown CL, Harbi K, Alexander LR, Coker AL, Fernandez ME, Brandt HM, Fadden MK, Hull PC (2015) J Health Care Poor Underserved 26(4): 1440-55
    › Primary publication · 26548691 (PubMed) · PMC5512158 (PubMed Central)
  4. Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. Hover LD, Young CD, Bhola NE, Wilson AJ, Khabele D, Hong CC, Moses HL, Owens P (2015) Cancer Lett 368(1): 79-87
    › Primary publication · 26235139 (PubMed) · PMC4554828 (PubMed Central)
  5. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer. Wilson AJ, Saskowski J, Barham W, Yull F, Khabele D (2015) J Ovarian Res : 46
    › Primary publication · 26215403 (PubMed) · PMC4517540 (PubMed Central)
  6. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D (2015) Oncotarget 6(25): 21353-68
    › Primary publication · 25972361 (PubMed) · PMC4673270 (PubMed Central)
  7. KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine. Stewart ML, Tamayo P, Wilson AJ, Wang S, Chang YM, Kim JW, Khabele D, Shamji AF, Schreiber SL (2015) Cancer Res 75(14): 2897-906
    › Primary publication · 25968887 (PubMed) · PMC4506246 (PubMed Central)
  8. Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells. Carrillo AM, Hicks M, Khabele D, Eischen CM (2015) Mol Cancer Res 13(8): 1197-205
    › Primary publication · 25964101 (PubMed) · PMC4543442 (PubMed Central)
  9. Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours. Fadare O, Zhao C, Khabele D, Parkash V, Quick CM, Gwin K, Desouki MM (2015) Pathology 47(2): 105-11
    › Primary publication · 25551297 (PubMed)
  10. Ovarian mucinous tumor with malignant mural nodules: dedifferentiation or collision? Desouki MM, Khabele D, Crispens MA, Fadare O (2015) Int J Gynecol Pathol 34(1): 19-24
    › Primary publication · 25473748 (PubMed)
  11. Preferential effect of akt2-dependent signaling on the cellular viability of ovarian cancer cells in response to EGF. Khabele D, Kabir SM, Dong Y, Lee E, Rice VM, Son DS (2014) J Cancer 5(8): 670-8
    › Primary publication · 25258648 (PubMed) · PMC4174511 (PubMed Central)
  12. The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer. Khabele D (2014) Front Oncol : 111
    › Primary publication · 24904826 (PubMed) · PMC4033132 (PubMed Central)
  13. Differential vimentin expression in ovarian and uterine corpus endometrioid adenocarcinomas: diagnostic utility in distinguishing double primaries from metastatic tumors. Desouki MM, Kallas SJ, Khabele D, Crispens MA, Hameed O, Fadare O (2014) Int J Gynecol Pathol 33(3): 274-81
    › Primary publication · 24681739 (PubMed) · PMC4144715 (PubMed Central)
  14. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D (2014) Gynecol Oncol 133(3): 599-606
    › Primary publication · 24631446 (PubMed) · PMC4347923 (PubMed Central)
  15. HPV vaccine use among African American girls: qualitative formative research using a participatory social marketing approach. Hull PC, Williams EA, Khabele D, Dean C, Bond B, Sanderson M (2014) Gynecol Oncol : S13-20
    › Primary publication · 24491412 (PubMed) · PMC3966189 (PubMed Central)
  16. Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. Collins Y, Holcomb K, Chapman-Davis E, Khabele D, Farley JH (2014) Gynecol Oncol 133(2): 353-61
    › Primary publication · 24406291 (PubMed) · PMC4079541 (PubMed Central)
  17. Aspirin Blocks EGF-stimulated Cell Viability in a COX-1 Dependent Manner in Ovarian Cancer Cells. Cho M, Kabir SM, Dong Y, Lee E, Rice VM, Khabele D, Son DS (2013) J Cancer 4(8): 671-8
    › Primary publication · 24155779 (PubMed) · PMC3805995 (PubMed Central)
  18. Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model. Wilson AJ, Barham W, Saskowski J, Tikhomirov O, Chen L, Lee HJ, Yull F, Khabele D (2013) J Ovarian Res 6(1): 63
    › Primary publication · 24020521 (PubMed) · PMC3846584 (PubMed Central)
  19. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, Ebright RY, Stewart ML, Ito D, Wang S, Bracha AL, Liefeld T, Wawer M, Gilbert JC, Wilson AJ, Stransky N, Kryukov GV, Dancik V, Barretina J, Garraway LA, Hon CS, Munoz B, Bittker JA, Stockwell BR, Khabele D, Stern AM, Clemons PA, Shamji AF, Schreiber SL (2013) Cell 154(5): 1151-1161
    › Primary publication · 23993102 (PubMed) · PMC3954635 (PubMed Central)
  20. Adrenal gland metastasis is an unusual manifestation of endometrial cancer. Zaidi SS, Lakhani VT, Fadare O, Khabele D (2013) Case Rep Surg : 428456
    › Primary publication · 23984164 (PubMed) · PMC3748408 (PubMed Central)
  21. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. Wells CE, Bhaskara S, Stengel KR, Zhao Y, Sirbu B, Chagot B, Cortez D, Khabele D, Chazin WJ, Cooper A, Jacques V, Rusche J, Eischen CM, McGirt LY, Hiebert SW (2013) PLoS One 8(7): e68915
    › Primary publication · 23894374 (PubMed) · PMC3718806 (PubMed Central)
  22. TR3 modulates platinum resistance in ovarian cancer. Wilson AJ, Liu AY, Roland J, Adebayo OB, Fletcher SA, Slaughter JC, Saskowski J, Crispens MA, Jones HW, James S, Fadare O, Khabele D (2013) Cancer Res 73(15): 4758-69
    › Primary publication · 23720056 (PubMed) · PMC3944084 (PubMed Central)
  23. A case of extrauterine endometrial stromal sarcoma in the colon diagnosed three decades after hysterectomy for benign disease. Ayuso A, Fadare O, Khabele D (2013) Case Rep Obstet Gynecol : 202458
    › Primary publication · 23710389 (PubMed) · PMC3655501 (PubMed Central)
  24. Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas. Fadare O, James S, Desouki MM, Khabele D (2013) Ann Diagn Pathol 17(5): 430-3
    › Primary publication · 23706170 (PubMed) · PMC4079538 (PubMed Central)
  25. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Fadare O, Gwin K, Desouki MM, Crispens MA, Jones HW, Khabele D, Liang SX, Zheng W, Mohammed K, Hecht JL, Parkash V (2013) Mod Pathol 26(8): 1101-10
    › Primary publication · 23524907 (PubMed) · PMC3886836 (PubMed Central)
  26. Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance. Fadare O, Liang SX, Crispens MA, Jones HW, Khabele D, Gwin K, Zheng W, Mohammed K, Parkash V, Hecht JL, Desouki MM (2013) Hum Pathol 44(8): 1508-15
    › Primary publication · 23465280 (PubMed) · PMC3888088 (PubMed Central)
  27. Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy. Wilson AJ, Cheng YQ, Khabele D (2012) J Ovarian Res 5(1): 12
    › Primary publication · 22531354 (PubMed) · PMC3394212 (PubMed Central)
  28. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Wilson AJ, Holson E, Wagner F, Zhang YL, Fass DM, Haggarty SJ, Bhaskara S, Hiebert SW, Schreiber SL, Khabele D (2011) Cancer Biol Ther 12(6): 484-93
    › Primary publication · 21738006 (PubMed) · PMC3218590 (PubMed Central)
  29. Pleomorphic liposarcoma of the uterine corpus with focal smooth muscle differentiation. Fadare O, Khabele D (2011) Int J Gynecol Pathol 30(3): 282-7
    › Primary publication · 21464725 (PubMed)
  30. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Bhaskara S, Knutson SK, Jiang G, Chandrasekharan MB, Wilson AJ, Zheng S, Yenamandra A, Locke K, Yuan JL, Bonine-Summers AR, Wells CE, Kaiser JF, Washington MK, Zhao Z, Wagner FF, Sun ZW, Xia F, Holson EB, Khabele D, Hiebert SW (2010) Cancer Cell 18(5): 436-47
    › Primary publication · 21075309 (PubMed) · PMC3004468 (PubMed Central)
  31. The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21. Son DS, Wilson AJ, Parl AK, Khabele D (2010) Cancer Biol Ther 9(11): 928-35
    › Primary publication · 20404564 (PubMed) · PMC4047717 (PubMed Central)
  32. Expression of Keratin 8 and TNF-Related Apoptosis-I Inducing Ligand (TRAIL) in Down Syndrome Placentas. Klugman SD, Gross SJ, Liang J, Livne K, Gross B, Khabele D, Lopez-Jones M, Cordero DR, Reznik S (2008) Placenta 29(4): 382-4
    › Primary publication · 18343496 (PubMed) · PMC2475678 (PubMed Central)
  33. Ovarian volume measurements in mice with high-resolution ultrasonography. Lyshchik A, Hobbs SB, Fleischer AC, Khabele D, Son DS, Gore JC, Price RR (2007) J Ultrasound Med 26(10): 1419-25
    › Primary publication · 17901144 (PubMed)
  34. Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. Son DS, Parl AK, Rice VM, Khabele D (2007) Cancer Biol Ther 6(8): 1302-12
    › Primary publication · 17712227 (PubMed)
  35. Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. Daikoku T, Tranguch S, Chakrabarty A, Wang D, Khabele D, Orsulic S, Morrow JD, Dubois RN, Dey SK (2007) Cancer Res 67(11): 5285-92
    › Primary publication · 17545608 (PubMed)